Tag Archive for: Synendos Therapeutics

Synendos Therapeutics AG Granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510

Synendos Therapeutics transitions to a clinical-stage biotech company developing innovative Endocannabinoid System (ECS) treatments for neuropsychiatric, neuroinflammatory and other Central Nervous System (CNS) disorders Clinical Trial will investigate the safety, tolerability and pharmacokinetics of Synendos’ first-in-class ECS modulator BASEL, Switzerland – 18 January 2024 – Synendos Therapeutics AG (Synendos), a world leader in innovative Endocannabinoid System […]

Synendos Therapeutics Appoints Scientific Advisory Board

Synendos Therapeutics is thrilled to announce the formation of the Scientific Advisory Board composed of prominent scientists and clinicians with significant CNS expertise. Read more